NCT07701005Completed
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity
Early Changes in Non-Invasive Hepatic and Metabolic Indices After Incretin-Based Therapy in Patients With Overweight or Obesity: Real-World Evidence From a Turkish Cohort
Source: ClinicalTrials.gov · Last updated 15 Jul 2026
Brief summary (registry, in English)
This single-center, retrospective observational cohort study evaluated early changes in non-invasive hepatic and metabolic indices (FIB-4, APRI, HSI, and the triglyceride-glucose \[TyG\] index) in adults with overweight or obesity who received once-weekly subcutaneous semaglutide or tirzepatide for metabolic risk reduction related to metabolic dysfunction-associated steatotic liver disease (MASLD). Baseline and follow-up (minimum 12 weeks) clinical, anthropometric, and laboratory data from 154 patients treated at a single tertiary-care center in Turkey were analyzed. The study assessed whether short-term incretin-based therapy was associated with changes in fibrosis-related indices (FIB-4, APRI) versus steatosis- and insulin resistance-related indices (HSI, TyG), and identified independent predictors of these changes using multivariable linear regression.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 154 (actual)
- First submitted
- 7 Jul 2026
- Start date
- 1 Jan 2024
- Primary completion date
- 30 Mar 2026
- Lead sponsor
- Goztepe Prof Dr Suleyman Yalcın City Hospital
- Diseases
- Obesity
- NCT number
- NCT07701005
What you commit to
- Study type: Observational
- Participants enrolled: 154
- From 1 Jan 2024 to the primary completion date, 30 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior bariatric surgery
- Initiation or dose modification of pioglitazone, SGLT-2 inhibitors, or high-dose vitamin E within 3 months before baseline
- Concurrent use of known hepatotoxic agents (e.g., amiodarone, methotrexate)
Other illness
- Chronic liver disease of other etiology (viral hepatitis, autoimmune hepatitis, hemochromatosis, Wilson's disease)
Lab values
- Missing clinical, anthropometric, or laboratory data at baseline or follow-up
Other
- Significant alcohol consumption (\>30 g/day for men; \>20 g/day for women)
Who the study is looking for
- Adults aged 18 years or older
- Overweight (BMI 25.0-29.9 kg/m²) or obesity (BMI ≥30.0 kg/m²)
- Considered at increased metabolic risk for MASLD (overweight/obesity plus ≥1 additional cardiometabolic risk factor)
- Continuous treatment with subcutaneous semaglutide or tirzepatide for at least 12 weeks
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Facility: Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçın City Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.